Electronic Patient-Reported Outcomes (ePROS) Market is expected to reach US$ 2,868.00 Million by 2031

Instruments Segment to Bolster Electronic Patient-Reported Outcomes (ePROS) Market Growth During 2023–2031

According to our new research study on "Electronic Patient-Reported Outcomes (ePROS) Market Forecast to 2031 – Global Analysis – by Delivery Mode, Application, and End User," the market was valued at US$ 843.77 million in 2023 and is projected to reach US$ 2,868.00 million by 2031; it is anticipated to record a CAGR of 16.5% from 2023 to 2031. The electronic patient-reported outcomes (ePROS) market report emphasizes the trends prevalent in the global market, along with drivers and deterrents affecting its growth.

The practice of outsourcing clinical studies with a massive rise in the number of trials and the flourishing pharmaceutical industry with a surge in research and development activities are contributing to the electronic patient-reported outcomes (ePROS) market growth. However, the data privacy and security issues hamper market growth. Further, the integration of artificial intelligence and machine learning with ePROS platforms is expected to bring new electronic patient-reported outcomes (ePROS) market trends in the coming years.

Electronic Patient-Reported Outcomes (ePROS) Market Share, by Region, 2023 (%)

Source: The Insight Partners Analysis

Increasing Focus on Patient-Centered Care Drive Electronic Patient-Reported Outcomes (ePROS) Market

The growing emphasis on patient-centered care contributes to the growing electronic patient-reported outcomes (ePROS) market size. Tools that gather patient feedback in real-time are in high demand owing to the shift toward prioritizing patient experiences, outcomes, and preferences. The real-time tracking of patient-reported health outcomes is made possible by ePROs as healthcare becomes more personalized and value-based. Better health outcomes are supported by ensuring treatments are tailored to each patient's needs. The use of digital tools such as ePROs has increased as the focus of healthcare facilities shifts to patient experience and satisfaction. With the help of this technology, patients can have less stress and receive continuous feedback by giving healthcare providers access to precise data. This change drives innovation in digital health technologies, supporting the integration of ePROs into medical procedures. For instance, healthcare providers can easily monitor patient outcomes owing to the growing integration of ePRO tools with electronic health record (EHR) systems. This facilitates the alignment of clinical decisions with the preferences and experiences that the patient has reported.

The electronic patient-reported outcomes (ePROS) market analysis has been carried out by considering the following segments: delivery mode, application, end user, and geography. The electronic patient-reported outcomes (ePROS) market, based on delivery mode, is divided into cloud based and on-premise. The cloud based segment held a larger share of the market in 2023. Cloud-based ePRO systems allow providers to record patients' opinions about their health conditions, treatments, and quality of life, which is essential given the increasing focus on patient-centered healthcare. Large-scale patient data processing and analysis capabilities are increasingly needed in cloud-based ePRO systems owing to the growing use of AI, machine learning, and data analytics in healthcare. In addition, cloud-based ePRO systems allow decentralized trials to collect data more effectively, especially in remote areas, eliminating the need for patients to visit clinical sites. For example, Varian Medical Systems, Inc. offers a cloud-based mobile service-the Noona platform—intended to record PROs in oncology. By utilizing electronic patient-reported outcomes (ePROs) and oncology-specific questionnaires for remote symptom management, Noona provides enhanced capabilities compared to a typical patient portal. In addition to improving patient outcomes, the collection and tracking of ePROs facilitates effective communication and propels cancer research. Because of these advantages, cloud-based ePRO systems are being adopted more quickly across the healthcare industry, fueling the segment growth.

By application, the market is segmented into oncology, respiratory, and others. The oncology segment dominated the market in 2023. Electronic patient-reported outcome (ePRO) assessment can be valuable in palliative oncology settings, supporting clinicians' and patients' clinical activities. The benefits of ePRO systems, including enhanced quality of life and care, real-time monitoring, and efficient communication, were consistent with the increasing form of research highlighting the advantages of using technology in cancer treatment. This system has the potential to address the different issues in cancer care. For instance, in July 2024, a research team at the University of California, Irvine, created and executed an intervention to improve cancer care support services for patients who belong to racial and ethnic minorities and are undergoing chemotherapy. Using the web-based electronic patient-reported outcome tool, people can enter their health information into a computer, tablet, or smartphone. The ePRO and digital analytics were used in this study and were available in several languages. Thus, this innovative strategy plays a crucial role in addressing the ongoing health disparities that racial and ethnic minorities experience in cancer care. Further, monitoring electronic patient-reported outcomes (ePRO) has gained traction as a potential way to improve cancer patient care and surveillance over the last ten years.

Based on end user, the electronic patient-reported outcomes (ePROS) market is segmented into CROs, pharmaceutical companies, and others. The pharmaceutical companies segment held the largest electronic patient-reported outcomes (ePROS) market share in 2023. Pharmaceutical companies' strategies and operations are heavily influenced by electronic patient-reported outcomes (ePROs), particularly with the shift in the industry toward patient-centered care and value-based healthcare. Pharmaceutical companies can improve drug development processes, improve market access strategies, and collect vital data on patient experiences with the help of ePRO tools. Businesses can more accurately evaluate a drug's effect on patients by integrating ePRO and clinical metrics such as biomarkers. As a result, detailed information about the safety and effectiveness of drugs is produced, increasing the likelihood of regulatory approval and better-designed trials. Moreover, adaptive trial designs made possible by ePRO enable the modification of treatments in response to immediate patient feedback. Pharmaceutical companies rely heavily on ePRO as a driver because it allows them to gather critical patient-centric data that improves clinical trials, increases patient engagement, and supports market access and regulatory approval. By assisting businesses in showcasing the benefits of their treatments in terms of actual results, ePRO tools help promote the transition to more individualized and patient-centered care.

The geographic scope of the electronic patient-reported outcomes (ePROS) market report includes the assessment of the market performance in North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and Rest of Asia Pacific), South & Central America (Brazil, Argentina, and Rest of South & Central America), and the Middle East & Africa (South Africa, Saudi Arabia, the UAE, and Rest of the Middle East & Africa).  

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com